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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.020The molecular genetic alterations underlying the development and diversity of salivary gland carci-
nomas are largely unknown. To characterize these events, comparative genomic hybridization analysis
was performed, using a single-nucleotide polymorphism microarray platform, of 60 fresh-frozen spec-
imens that represent the main salivary carcinoma types: mucoepidermoid carcinoma (MEC), adenoid
cystic carcinoma (ACC), and salivary duct carcinoma (SDC). The results were correlated with the clini-
copathologic features and translocation statuses to characterize the genetic alterations. The most
commonly shared copy number abnormalities (CNAs) in all types were losses at chromosomes 6q23-26
and the 9p21 region. Subtype-speciﬁc CNAs included a loss at 12q11-12 in ACC and a gain at 17q11-12
in SDC. Focal copy number losses included 1p36.33-p36-22 in ACC, 9p13.2 in MEC, and 3p12.3-q11-2,
6q21-22.1, 12q14.1, and 12q15 in SDC. Tumor-speciﬁc amplicons were identiﬁed at 11q23.3 (PVRL1) in
ACC, 11q13.3 (NUMA1) in MEC, and 6p21.1 (CCND3), 9p13.2 (PAX5), 12q15 (CNOT2/RAB3IP), 12q21.1
(GLIPR1L1), and 17q12 (ERBB2/CCL4) in SDC. A comparative CNA analysis of fusion-positive and fusion-
negative ACCs and MECs revealed relatively lower CNAs in fusion-positive tumors than in fusion-negative
tumors in both tumor types. An association between CNAs and high grade and advanced stage was
observed in MECs only. These ﬁndings support the pathogenetic segregation of these entities and deﬁne
novel chromosomal sites for future identiﬁcation of biomarkers and therapeutic targets. (Am J Pathol
2013, 182: 2048e2057; http://dx.doi.org/10.1016/j.ajpath.2013.02.020)Supported in part by the National Institute of Dental and Craniofacial
Research, the Ofﬁce of Rare Diseases Research grant U01DE019765, the
Head and Neck SPORE (Specialized Programs of Research Excellence)
program grant P50 CA097007, The Kenneth D. Muller Professorship, and
National Cancer Institute grant CA-16672.
The content is solely the responsibility of the authors and does not neces-
sarily represent the ofﬁcial views of the National Cancer Institute or the NIH.Salivary gland carcinomas (SGCs) comprise numerous
morphological, biological, and clinically diverse entities that
sometimes have overlapping diagnostic and management
difﬁculties.1,2 The heterogeneity of these tumors has largely
been linked to their derivation from different segments of
the ductal-acinar unit of the salivary glands. In that context,
tumors derived from the terminal duct are composed of dual
epithelial and myoepithelial cells and are less aggressive
than those derived from purely epithelial-lined ductal
segments. These behavioral differences have been, at least
in part, attributed to the suppressive role of myoepithelial
cells.3e5 Although numerous subtypes have been recog-
nized, mucoepidermoid carcinoma (MEC), adenoid cystic
carcinoma (ACC), and salivary duct carcinoma (SDC) arestigative Pathology.
.the most common salivary malignancies, with a combined
incidence of 75%. In addition to representing the major
histopathological categories, they manifest disparate inter-
tumoral phenotypic, genetic, and clinical characteristics.6e13
Surgical resection with postoperative radiotherapy is the
primary treatment for SGCs, but patients with nonresectable,
recurrent, and metastatic disease have limited therapeutic
Genomic Analysis of Salivary Gland Cancersoptions. Several chemotherapeutic and targeted agent trials
have been conducted in patients with advanced SGCs, with
minimal success.6,7,14e18 However, the results of these trials
were disappointing and complicated by the inclusion of
different phenotypes, patients with variable clinicopathologic
characteristics, and small sample sizes. These shortcomings,
together with the lack of progress in understanding the events
associated with development of salivary cancers, highlight
the need for novel biomarker-based trial concepts. Identi-
fying the genetic and molecular events associated with SGC
evolution and clinical diversity is central to future progress in
their management.16e18
High-resolution, microarray-based, comparative genomic
hybridization and single-nucleotide polymorphism (SNP)
array platforms have greatly advanced the detection of
genomic alterations and have led to the localization of critical
genetic aberrations that are associated with major solid
tumors.18e29 Furthermore, the ability to detect focal DNA
loss as a result of homozygous deletion, hemizygosity, and/or
copy number neutral loss of heterozygosity (CNN-LOH)
allows for further in-depth identiﬁcation of previously
unknown events.30,31 Using these tools, investigators were
able to characterize and deﬁne the genetic alteration in
several solid human malignant tumors.21,22,26,27
We hypothesized that early molecular genetic alterations
are shared among all SGCs and that the subsequent acqui-
sition of type-speciﬁc events underlies their morphological
and biological diversity. To test this hypothesis and to
characterize molecular genetic alterations of SGCs, we used
an oligonucleotide SNP array platform and in-depth infor-
matics programs.
Materials and Methods
Tumors and DNA Sample Processing
We searched the head and neck pathology database at The
University of TexasM.D.AndersonCancerCenter (Houston,
TX) to identify all patients with SGCs who had been treated
surgically from 1995 to 2008. Twenty cases from each tumor
type, ACCs, MECs, and SDCs were selected based on the
availability of at least 1.0 g of fresh-frozen tumor tissues.
Seventeen salivary gland tissues (10 from matching tumor
cases and seven from neck resections from patients with other
diseases) were used as control (Supplemental Table S1). The
20 ACCs had previously been included in our earlier
comparative genomic hybridization analysis.32 The tissues
had been harvested immediately after resection by experi-
enced head and neck pathologists (A.E.N.), placed in liquid
nitrogen, and stored at 80C until use. Frozen sections of
each tissue specimen were evaluated for tumor content and
phenotypic viability. Specimens with >20% of host non-
neoplastic elements underwent macrodissection to remove
host elements to enrich tumor content to >80%. One ACC
tumor was disqualiﬁed because of excessive stroma; of the 59
tumor specimens, 14 had undergone macrodissection. AllThe American Journal of Pathology - ajp.amjpathol.orgtissues were obtained according to an Institutional Review
Boardeapproved protocol for nonmucosal head and neck
cancer.
DNA Extraction
Fresh-frozen tissue was processed using the Gentra Puregene
tissue kit (Qiagen, Valencia, CA). In brief, normal and tumor
tissues were carefully dissected, and proteinase K was
immediately added for cell digestion. After protein precipi-
tation, DNA was precipitated using isopropanol, followed by
a 70% ethanol washing procedure. Puriﬁed DNA was dis-
solved and eluted in DNA hydration solution and stored at
80C. The quality of DNA was assessed using electropho-
resis and nanodropmeasurement.A 260/280wavelength ratio
of at least 1.8 was used to qualify specimens for analysis.
Microarray Analysis
We used the Affymetrix 250k Nsp SNP array (Affymetrix,
Inc., Santa Clara, CA) to survey the genotype and DNA copy
number abnormality (CNA) data for 59 tumor specimens and
17 healthy salivary gland specimens. Each array contains
261,563 SNP sites, which are approximately uniformly
distributed throughout the genome. The SNP site mapping
information was provided by Affymetrix, Inc., using human
genome sequence version (National Center for Biotech-
nology Information) NCBI36/hg18. Two samples were
repeatedly sampled to assess data reproducibility.
RT-PCR Analysis of Chimeric Fusions
Screening for the t(6;9)/MYB-NFIB and t(11;19)/CTRC1-
MAML2 fusion transcripts was performed as previously
described.3,12,13
FISH Analysis
We performed ﬂuorescence in situ hybridization (FISH)
analysis on touch preparations from fresh tumor fragments
using standard, commercially available, spectrum orangee
and spectrum greenelabeled probes for ERBB2 ampliﬁcation
(PathVysion HER-2 DNA probe kit; Abbott Laboratories,
Des Plaines, IL). Known ampliﬁed samples and normal
parotid tissue were used as the positive and negative controls,
respectively. Tumor sampleswere evaluated for ampliﬁcation
patterns; we also determined the number of centromeric probe
signals of the corresponding chromosomes, with at least 100
cells evaluated per slide. Ampliﬁcation was deﬁned as the
presence of >10 copies per tumor cell in 20% of cells. We
also performed an FISH analysis on parafﬁn sections of
selected cases to verify 1p35-36 deletions. We used the
bacterial artiﬁcial chromosome clones, RP11-219 C24 and
RP-11-163M9, and a control clone, RP11-201K10 (1q21), as
previously described.32 For PAX5 gene ampliﬁcation, we
used an orange-labeled bacterial artiﬁcial chromosome
(BAC) clone (RP11-243F8) and a green-labeled centromeric2049
Figure 1 Distribution of CNAs across the human genome in ACCs, MECs,
and SDCs. The heights of the red regions illustrate the number of samples
with copy number gains; the x axis shows the genomic order of the probed
segments. The heights of the green regions represent the number of copy
number losses. CNAs in chromosome X are affected by sex and were not
counted.
Zhang et alchromosome 9 probe on case SDC10 (PAX5 ampliﬁcation)
and a control negative tumor.
IHC Staining
We performed immunohistochemical (IHC) staining for
human epidermal growth factor receptor 2 (HER-2) using the
automated BOND MAX strainer (Vision Biosystems Wav-
erley, Australia) on a parafﬁn section (4 mm thick) prepared
from the ﬁve tumors with gene ampliﬁcation, according to a
previously published protocol.33 The antieHER-2 mono-
clonal antibody (clone e2-4001, mouse, 1:300 was used;
Thermo Fisher Scientiﬁc, Fremont, CA) and the secondary
conjugate antibody, applied and counterstained with H&E.
HER-2 membrane staining was evaluated on the basis of
previously described criteria.33 The IHC staining for cyclin
D3 (CCND3) was performed using anti-CCND3 polyclonal
antibody (clone C-16, rabbit, 1:100; Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA) after citrate buffer antigen
retrieval for 30 minutes.
Statistical Analysis
The data analyses were performed using Partek and R soft-
ware packages. We used Partek Genomics Suite software (St.
Louis, MO) to extract the copy number and B-allele fraction
data from the CEL ﬁles of the Affymetrix SNP array raw data.
The subsequent steps of the analyseswere performed using R.
A scanning window of 509 SNPs and the median was used to
represent the copy number of the DNA segment enclosed in
the data was applied. The raw data CEL ﬁles, the R-scripts,
and the processed DNA copy number data used in the raw
data analyses are available from the Gene Expression
Omnibus database (http://www.ncbi.nlm.nih.gov/geo; acces-
sion number GSE44434).
Broad CNA Analysis
To characterize broad CNAs, we used the running median
smoothing method to denoise the copy number data, with
a scanning window of 509 SNP probes (approximately 5.5
million bp of the genome) was applied. Accordingly, gains and
losses less than half the window size (2.75 million bp) were
excluded from the broad CNA analysis. The ﬁve-s rule was
used to determine whether the gain or loss was signiﬁcant; s
represents the estimated dispersion of the copy number
measurement for a given chromosomal segment enclosed by
a scanning window. This was calculated as follows:
sZ
madðCNi FCNiþ1Þﬃﬃﬃ
2
p ð1Þ
in which mad stands for the median absolution deviation
and CNi  CNiþ1 stands for the differential between
nonoverlapping consecutive scanning windows. If the copy
number proﬁle can be regarded as a piecewise constant plus
gaussian noise, this formulation will provide a robust2050estimate of the SD. The gain or loss of a chromosomal
segment in the scanning window was deﬁned as the median
copy number differing signiﬁcantly from two.
Focal CNA Analysis
To identify focal CNAs, a double-ﬁltering strategy to process
copy number proﬁles was used with a median smoothing
method to denoise the copy number data with a scanning
window width of 25 SNP probes. To evaluate the effects of
broad CNAs, we reapplied the running median smoothing,
with a scanning window the width of 1625 SNP probe sets.
The twice-smoothed copy number data were then subtracted
from the once-smoothed copy number data to identify the
focal CNA proﬁle; the resulting CNA proﬁle included an
aberrant segment of<2.7million bp. Supplemental Figure S1
illustrates the relationship between focal and broad CNAs.
Double ﬁltering caused focal alterations to become prominent
peaks and valleys; the copy number proﬁle of most of the
genome appears ﬂat, with perturbations from a small amount
of noise. To evaluate the statistical signiﬁcance of the focal
CNAs, we used the ﬁve-s rule. The procedure was similar to
that used to evaluate the broad CNAs, except that theajp.amjpathol.org - The American Journal of Pathology
Table 1 Recurrent Focal CNAs in Major SGCs
SNP ID Chromosome Cytoband Position
ACC (%) MEC (%) SDC (%)
GeneG L G L G L
2131660 1 p36.33 1145994 11 0 10 10 10 0 TP73
1988527 6 q27 168176083 16 16 0 20 5 5 FGFR1OP
1822252 7 p22.1 5642226 5 0 5 15 10 5 RNF216
1996220 9 p21.3 21763222 0 5 5 10 0 10 CDKN2A
2191519 9 p21.3 22115503 0 5 0 5 0 20 CDKN2A
2185617 10 q11.22 47062478 11 5 10 15 10 0 ANAX8
1822332 13 q31.1 83036907 5 5 0 5 5 0 SLITRK1
1942128 14 q11.2 19417144 32 32 35 45 40 50 APEX1
4204773 15 q11.2 19163125 21 37 45 25 35 25 POTEB
1943770 15 q11.2 19912458 32 32 40 25 45 20 OR4N4
2249545 16 p13.2 7092171 5 0 5 5 0 0 A2BP1
1822964 16 p11.2 34307201 16 5 5 25 10 0 TP53TG3
2200283 17 p13.3 285707 0 0 0 0 15 10 RPH3AL
2264661 17 q12 31489488 11 11 5 10 20 10 CCL3L1
2005155 17 q12 34949761 0 0 0 0 25 0 ERBB2
2029077 17 q21.31 41602401 16 26 50 40 20 35 MAPT
4222078 18 p11.32 1738722 5 5 5 0 5 5 None
4240882 20 p12.1 14798101 0 5 0 5 0 5 MACROD2
1919387 22 q11.21 18703211 0 5 0 20 5 0 GGT2
2192475 22 q11.22 20825481 0 11 15 0 0 5 VPREB1
4207761 X p22.33 2581725 26 0 10 0 15 0 CD99
2170987 X q22.3 103915401 5 5 0 0 0 0 IL1RAPL2
The genomic loci were identiﬁed from SNP probe positions in which the variance focal CNA proﬁle peaked across samples. Loci with more than three
signiﬁcant focal CNAs are listed. A complete list can be found in Supplemental Table S2.
G, gain; L, loss.
Genomic Analysis of Salivary Gland Cancersestimated dispersion of the focal copy number proﬁle was
calculated as follows:
sfZ
madðFCNi FCNiþ1Þﬃﬃﬃ
2
p ð2Þ
in which mad represents the median absolute deviation and
FCNi  FCNiþ1 denotes the difference in copy numbers
between nonoverlapping, consecutive scanning windows.
The procedure resembles that used to evaluate broad CNAs,
except for a smaller scanning window size. Because smaller
scanning windows involve fewer SNP probes, the focal CNA
proﬁle contains a higher level of noise than does the broad
CNA proﬁle. Therefore, sf is higher than s.
Because focal gain or loss involves numerous SNPs, we
grouped focal CNAs as discrete events on the basis of the
deﬁned focal CNA proﬁle maximum across samples.
Allele-Speciﬁc Copy Number Analysis
To compute the allele-speciﬁc copy number for a genomic
segment, we ﬁrst collected the B-allele fraction data from
the segment:
RsetZfR : jR 0:5j< Quantile ðjR 0:5j; bÞg; ð3Þ
where R is a B-allele fraction data point and b is a threshold
value set to be 0.15. This threshold was estimated from the
frequency of heterozygous SNP loci probed on the array.The American Journal of Pathology - ajp.amjpathol.orgApproximately 85% of the probed sites on the array are
homozygous. The estimate of the R value of the segment
was computed as follows:
bRZmodeðRsetÞ; ð4Þ
in which the mode value is the most common. The two
allele-speciﬁc copy numbers were obtained as follows:
CNaZCN
0:5þ bRset
 ð5Þ
CNbZCN
0:5 bRset
: ð6Þ
The sum of CNa and CNb is the total copy number that
reﬂects the broad-scale CNA proﬁle. However, the allele-
speciﬁc CNA analysis could not identify localized CNAs
that spanned less than half the size of the scanning window,
indicating that localized CNAs that were <2.7 million bp in
the chromosomes were ignored in the broad CNA proﬁles
described in this study.
Results
Fifty-nine tumors qualiﬁed for the analysis [one ACC
sample did not meet the minimum DNA quality requirement
(see Materials and Methods)]. Patients’ clinical and patho-
logical characteristics are presented in Supplemental Table
S1. The cohort was composed of 25 women and 34 men,
aged 21 to 91 years (mean, 56 years). Thirty-nine tumors2051
Table 2 Genomic Regions with CNN-LOH/UPD in Major SGCs
Chromosome Cytoband Position ACC (%) MEC (%) SDC (%)
1 p36.33ep36.22 775852e9341877 16 0 0
1 q43eq43 236829721e240601698 0 10 5
2 q11.2eq12.2 100704414e105985632 0 5 10
2 q14.2eq14.3 119250745e124670233 5 5 5
3 p24.3ep24.2 21618434e25295115 0 5 10
3 p12.3eq11.2 78686977e96257804 0 0 15
5 q33.2eq35.3 153512108e180629495 0 5 10
6 q21eq22.1 109415645e114741718 0 0 15
9 p24.3ep24.1 140524e6300829 0 10 5
9 p22.3ep22.1 15942197e18968625 11 5 0
9 p21.2ep21.1 27800651e31371316 11 0 0
9 p21.1ep13.2 31373712e37537256 5 10 0
9 p13.2eq21.13 37574687e73460374 0 15 0
9 q22.33eq31.1 99537571e104645839 0 10 5
9 q33.1eq33.1 117901921e121619119 5 5 5
9 q33.3eq34.3 128519158e140147760 5 5 5
10 q21.1eq21.1 57418162e61122758 5 5 10
10 q21.1eq21.3 61177020e66136170 0 5 10
11 p15.1ep14.3 20031569e23207906 5 0 10
11 p13ep13 31282908e35998329 5 0 10
11 p11.2eq11 44781630e56339353 0 0 10
11 q12.3eq13.4 62942205e74605123 0 5 10
11 q14.1eq14.3 84276650e88310071 0 5 10
12 q14.1eq14.3 58492903e64094393 0 0 15
12 q14.3eq15 64124796e68546087 0 0 10
12 q15eq21.1 68546631e73477497 0 0 15
12 q21.2eq21.31 78005428e83047419 0 0 10
12 q21.31eq21.33 83065065e88560841 0 5 10
14 q12eq21.1 29399863e39750495 5 0 10
18 q12.2eq12.3 34364676e39279784 0 5 10
Data show the number of CNN-LOH events that occurred in ACCs, MECs, and SDCs. The table lists only those genomic regions that had at least three events.
The events were identiﬁed using allele-speciﬁc CNAs that were signiﬁcantly different from the reference level, whereas the total CNA was not signiﬁcantly
different in a scanning window (for details, see Materials and Methods).
UPD, uniparental disomy.
Zhang et alwere located in major glands and 22 in minor glands; they
ranged from 1.0 to 15.0 cm (median, 4.7 cm).
We characterized large-scale broad and focal (narrow)
copy number DNA changes at different chromosomal
regions in all tumor specimens.
Broad CNA Analysis
Figure 1 and Supplemental Table S2 show the distributions of
broad gains and losses in ACCs, MECs, and SDCs. Gains and
losses of>2.7million bp (half thewindow size)were included
and counted as broad CNAs in the analysis. The results
revealed distinct differences among the subtypes:ACChad the
lowest level of aberrations, followed by MEC and SDC
(Figure 1). Common broad losses at chromosomes 1p36,
6q24, and 9p21 were found in tumors from all subtypes.
Preferential broad CNAs included four deletions at the 1p36,
6q27, and 12p14 and gains at the 9p22 and 18p11 regions in
ACCs only. In SDCs, broad CNAs that nearly included entire
arms or chromosomeswere observed and included gains at the
1q and 8q regions; chromosomes 7, 13, 15, and 21; and 1p, 2q,20524p, 5p, and 5q, 6q, 8p, 9p, 10q, 17p, and 8q regions. In general,
broad CNAs in MECs and SDCs had considerable overlap.
Focal CNA Analysis
Table 1 shows the distribution of and lists the signiﬁcant focal
CNAs found in at least three tumors. The most commonly
altered locus in tumors of different types was at 9p21.3; this
was found in one ACC, one MEC, and four SDCs. One MEC
sample also appeared to have a gain at the CDKN2A gene. In
addition, a focal gain at chromosome Xp21.3 (CD99 gene)
region in tumors from men was noted; because a copy of the
CD99 gene is also located on chromosome Y, the possibility
of a pseudoautosomal gain cannot be excluded. We also
identiﬁed alterations at loci on chromosomes 1p36.33,
14q11.2, 15q11.2, 17p21.31, and Xp22.3 in both tumors and
normal tissue (data not shown). CNAs at these loci have
previously been reported in healthy individuals.34 A
comparison of broad and focal CNA in one sample is illus-
trated in Supplemental Figure S1. The focal gain at 6q21, in
which theFYN gene (a membrane-associated tyrosine kinase)ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Validation of 17q12 ampliﬁcation in SDCs. Composite illustration of chromosome (Chr) 17q12 DNA (A) and corresponding ERBB2 gene ampli-
ﬁcation by FISH (B) and the expression by IHC analysis (C) in the four SDCs with amplicons at this location (SDCs 1, 2, 18, and 19) and case 15, an SDC with no
amplicons at this site, is far right (SDC15). Note the lack of ERBB2 gene ampliﬁcation and the low expression of this gene. The y axis shows copy number data
(in green). The red points were obtained by median smoothing (window size, 25). The x axis shows the position on chromosome 17. The position of the ERBB2
gene is marked by the gray vertical bars. C: The results of ERBB2 (HER-2) expression, which suggest that copy number gains contribute to elevated gene
expression. D: Corresponding light microscopic images (H&E stain) of each tumor.
Genomic Analysis of Salivary Gland Cancersis located, can be seen on the focal, but not the broad, CNA
proﬁle.
In this study, focal gains with a mean copy number higher
than six were considered to represent amplicons (Table 2).
Based on this deﬁnition, several amplicons in different
tumor types were identiﬁed. These included one amplicon
each at 11q13 and 11q23 in MECs and ACCs, respectively,
and four at the 17q12 locus in four different SDC tumors
(Figure 2A).
Allele-Speciﬁc Analysis
CNN-LOH represents loss of one allele and the duplication of
the other allele. Our search revealed multiple recurrent CNN-
LOH in ACCs,MECs, and SDCs (Table 3); the most common
were alterations at 12q14-15 in eight SDCs. Supplemental
Figure S1 shows an example of a CNN-LOH in which no
aberration on broadCNAdatawas noted; compensatoryCNN-
LOH alterations were noted at both alleles of chromosomes
5 and 9. We also found multiple CNN-LOH alterations at
centromeric 9p regions in tumors of all subtypes (two ACCs,
eight MECs, and one SDC). Interestingly, an MEC specimen
(MEC3) had no broad CNAs and only CNN-LOH in chro-
mosomes 2, 3, 5, 9, and 18. Paradoxically, CNN-LOHThe American Journal of Pathology - ajp.amjpathol.orgalterations were found within focal and broad copy number
loss regions in several tumors; these included loss at 1p36
in three ACC samples. Surprisingly, concurrent alterations
in nontumorous and tumor samples (case ACC5) at the
4q23-q25 region (Chr4:99350642-109772330, spanning ap-
proximately 10 million bp) were detected in multiple samples
(Supplemental Figure S2). Because normal tissues were ob-
tained from matched tissue specimens, the germline nature of
this event cannot be excluded.30,31
Relationship between CNAs and Gene Fusion
To determine whether CNAs differ on the basis of the
presence or absence of fusion genes, we performed t-tests to
scan for the mean copy number in fusion-positive and
fusion-negative tumors. The P values shown in Figure 3A
reﬂect the comparison of MYB-NFIB fusion-positive ACCs
and fusion-negative ACCs. Highly signiﬁcant associations
were seen at 6q25.2 (P Z 1.1  1011) and 9p13.3 (P Z
9.4 108) near the loci encodingMYB and NFIB. Figure 3,
B and C, shows CNA distributions stratiﬁed by fusion
status. Detailed copy number data at chromosomes 9 and 6
from fusion-positive and fusion-negative ACCs are shown
in Supplemental Figure S3. Fusion-positive ACCs had2053
Table 3 Amplicons at Different Chromosomal Regions in Major
SGCs
Sample Cytoband Position* CNA Gene
ACC1 11q23.3e24.1 118706909e122013373 9.9 PVRL1
MEC1 11q13.3eq13.4 70322842e71448250 7.2 NUMA1
SDC1 17q12 35084426e35264341 10.8 ERBB2
SDC10 12q15 68689573e69077882 7.0 CNOT2,
RAB3IP
SDC10 9p13.2 36791146e36905407 7.1 PAX5
SDC18y 17q12 31473221e31501499 6.9 CCL4
SDC19 17q12 35130293e35264341 6.6 ERBB2
SDC2 17q12 34786442e35130293 12.0 ERBB2
SDC4 6p21.1 41772099e42368678 6.0 CCND3
SDC7 12q21.1eq21.2 73790896e74456589 6.9 GLIPR1L1
A segment was deﬁned as an amplicon if the mean copy number was
higher than six.
*The genomic intervals of the segments are shown.
yThe amplicon at 17q12 in sample SDC18 encodes no known gene. The
nearest gene, CCL4, is shown instead.
Figure 3 Associationbetween CNAs andgene fusion in ACCs andMECs. The
x axis is ordered by chromosomal location. The vertical gray lines show the
boundaries of the chromosomes. In A and B, the y axis shows log10 (P values),
which were obtained from t-tests using copy number data for fusion-positive
and fusion-negative samples. The blue lines and asterisks indicate the sites
involved in gene fusion. Results regarding chromosome X should be ignored
because theywere affectedby sexdifferences.C andD: The distributionof CNAs
in fusion-positive and fusion-negative ACC samples. Gains are shown as red
bars; losses are shown as green bars. Similarly, E and F show the distribution of
CNAs in fusion-positive and fusion-negative samples of MECs, respectively.
Zhang et alfewer alterations than did fusion-negative tumors (Figure 3,
B and C), with exclusive loss at 4p and 6q and gain only at
9q. Loss at 12q and chromosome 14 and gains at chromo-
somes 18 and 22 characterized fusion-negative ACCs.
Interestingly, of the eight fusion-positive ACC samples,
four had breakpoints within 0.5 Mb of the MYB sites
(Supplemental Figure S3).
Similarly, Figure 3, DeF, illustrates the association
between CNAs and CRTC1-MAML2 fusion status in MECs.
Judging from the t-test P values, a signiﬁcant CNA differ-
ence was found at 11p15.1 (P Z 2.6 104) near CRTC1
but not near MAML2. There also appear to be signiﬁcant
loss (P < 2 106) loci at 3p22.1, 4p15.1, 12p12.3, and
17p12. Overall, fusion-negative tumors had more CNAs
than did fusion-positive tumors (Figure 3, E and F). Losses
of 1p, 2q, 4q, 6q, 10, and 13 and gains of chromosomes 12,
14, 16, and 18 were mainly found in fusion-negative MECs.
In both MECs and ACCs, fusion-positive tumors had rela-
tively fewer CNAs than did fusion-negative tumors.
Validation Findings
We validated the CNA ﬁndings at the 1p36, 9p13.2, and
17q12 regions by FISH or IHC analysis. Examples of ERBB2
in SDC cases (Figure 2B) and thePAX5 gene in one SDC case
(SDC10), as identiﬁed by the validation FISH, are shown in
Supplemental Figure S4. In ERBB2- and PAX5-ampliﬁed
cases (>8 copy numbers), the increasewas proportional to the
ploidy level of the tumor (Table 2). In addition, FISH analysis
using control probe RP11-201K10 (1q21) and 1p36 target
probes (RP11-219C24, RP11-163M9) were performed on
seven tumors with 1p36 loss and conﬁgured the loss of one or
two copies of 1p36 target probes.32 An IHC analysis using
antibodies speciﬁc to CCND3 (6p21.1) revealed high nuclear
expression of tumor cells in ampliﬁed cases (SDC4) and lack
of nuclear staining in nonampliﬁed cases (SDC10), as shown
in Supplemental Figure S5.2054Discussion
In this study, we characterized common and distinctive broad
and focal genetic alterations in major SGCs. In general, fewerajp.amjpathol.org - The American Journal of Pathology
Genomic Analysis of Salivary Gland Cancerschromosomal aberrations were found in ACCs than in MECs
and SDCs, underlining their perceived histological and clinical
differences. The most common broad CNAs shared in all
subtypes were located at chromosomes 6q23-26 and the 9p21
regions. Subtype-limited broad alterations were found in ACC
and included losses at the 6q and 12q22,35,36 regions and gains at
chromosomes 9p and 18. Although common loss at the 1p36
chromosome region was found in both ACC and SDC tumors,
different loci within this region are associated with ACC and
SDC.32 These ﬁndings, along with evidence of accelerated
tumor growth in mouse models with deletion at this chromo-
somal region, highlight the potential importance of this region
in oncogenesis.37e41 Moreover, these broad ﬁndings are in
agreement with those previously reported in individual studies
of these tumors.42e48
Our results highlight the localized chromosomal gains
and losses among and between different neoplasm types.
Surprisingly, multiple instances of localized gains and losses
at chromosome 14q11.4, 15q11.2, and 17q21.3 regions were
also observed in tumors and matched nonneoplastic salivary
tissues. These regions were previously reported to be altered
in North American population, presumably as common
polymorphic sites.34 More important, the ﬁnding of common
loss at the 9p21 locus, where theCDKN2A gene resides, in all
three tumor types. This ﬁnding lends further evidence for the
involvement of this gene in the early evolution of salivary
tumors.47We also noted a restricted loss of the 22q11.21 locus
that houses the RANBP1 gene in several MECs. The role of
this gene as a regulator of mitotic microtubule function and
organization in MEC tumorigenesis, however, is unknown.49
Paradoxically, focal gain at the 17q12 region and ampliﬁca-
tion of the ERBB2 gene were found in several SDCs.
Our more localized CNN-LOH analysis revealed multiple
restricted and shared alterations in several tumor subtypes.
CNN-LOH at chromosome 1p36.33 was found in ACC,
suggesting potential association with their ACC tumorigen-
esis.32 Strikingly, we noted concurrent CNN-LOH and focal
ampliﬁcations at chromosome 12q15 and 12q21 regions in
several SDCs. The ﬁndings indicate that these loci may either
contain critical genes or represent focal regions of genomic
instability. Interestingly, a recent study showed that an
average of six focal recurrent deletions per tumor occur in
human carcinomas, and these may result from a loss of tumor
suppressor gene, genomic instability (fragile site), hemi-
zygosity, and/or CNN-LOH.50 These ﬁndings, together with
evidence for an association between homologous recombi-
nation and these events at sites with no known tumor-
suppressor genes, lend further credence to our ﬁndings.50e52
Surprisingly, multiple mutually exclusive amplicons were
identiﬁed in different tumor types; these included one
amplicon in an ACC and one in an MEC at different sites on
the 11p regions and multiple nonoverlapping amplicons at
chromosomes 6p, 12q, and 17q in several SDCs. Not
surprisingly, some of the amplicons have also been identiﬁed
in high-grade mammary ductal carcinoma.31,53 Most of these
amplicons occurred at regions that lacked copy number gains,The American Journal of Pathology - ajp.amjpathol.orgsuggesting that a limited number of oncogenes reside at these
locations. Genes within these amplicons (Table 2), including
CCND3, NUMA1, PAX5, CNOT2, RAB3IP, GLIPR1L1,
ERBB2, CCL4, and PVRL1, have been linked to cell growth
and apoptosis in several tumor types.54e56 Of particular
interest is the identiﬁcation of amplicons at the 17q12 region,
where the ERBB2 gene resides, in several SDCs. Although
high ERBB2 expression has been reported, a thorough vali-
dation was needed by our group and others. Our validation
efforts conﬁrm the ampliﬁcation of known oncogenes
within these amplicons and the likelihood of their involve-
ment in the development and progression of some of these
tumors.33,56e59
A comparative analysis of fusion-positive and fusion-
negative ACCs and MECs revealed fewer CNAs in fusion-
positive than fusion-negative tumors (Supplemental Figure
S3). Interestingly, fusion-positive ACCs commonly had copy
number loss at or near the 6q25 and 9p23 translocation sites,
whereas fusion-negative ACCs had no alterations at these loci.
In contrast, no discernible CNA differences were found at the
11p or 19q fusion sites in fusion-negative or fusion-positive
MECs. Together, these results suggest that a genomic differ-
ence exists between tumors on the basis of fusion status; tumors
with fusions are most likely driven by this event, but studies of
human malignancies with fusion genes have revealed a similar
association.13,20 Fusion-negative tumors arise by a different
mechanism, such as genomic instability. Our clinicopathologic
analysis in this relatively small cohort revealed no association
between CNA and clinicopathologic features in patients with
ACC and SDC; however, high CNAs were much more
common in high-stage, high-grade, and clinically aggressive
MECs. Collectively, the speciﬁcity of the reciprocal trans-
locations in MECs and ACCs, along with the histogenetic and
biological differences, strongly supports their segregation into
distinct clinicopathologic entities in future targeted therapy
trials.
In conclusion, we identiﬁed several CNA differences
between SGC subtypes, supporting their genetic phenotypic
classiﬁcation for treatment.
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